Skip to content

Opko Health OPK Cumulative Gross Losses and Impairments

Discontinued — last reported Q4 '22

Cumulative Gross Losses and Impairments at other companies

Precigen logo
PrecigenPGEN
$36.19M+12.1%
Merck & Co. logo
Merck & Co.MRK
$531M0.0%

Segments

By segment

See full
Diagnostics$17.98M0.0%
Pharmaceutical$11.7M

Other financials

Income statement

See full
Revenue$124.2M-17.2%
Gross profit$45.8M+7.4%
Operating income-$51.0M+24.0%
Net income-$54.8M+18.9%
EPS (diluted)-$0.07+30.0%

Balance sheet

See full
Cash & equivalents$40.6M-62.5%
Total debt$52.8M-4.2%
Total equity$1.2B-8.2%
Total assets$1.9B-12.8%

Cash flow

See full
Operating cash flow-$19.3M+44.1%
CapEx$1.8M-42.6%
Free cash flow-$21.1M+44.0%

Valuation

See full
Market cap$1.14B+11.5%
P/S+0.5×

Profitability

See full
Gross margin36%+4.2pp
Operating margin-17.4%-5.6pp
Net margin-36.6%-44.8pp
FCF margin-30%+0.1pp

Returns & leverage

See full
Return on equity-16.9%-21.7pp
Debt / equity0.0×
Current ratio3.6×+1.1×

Where this comes from

Reported directly by Opko Health in its filing.

Tagged under the XBRL concept us-gaap:GoodwillImpairedAccumulatedImpairmentLoss.

The official record: Opko Health’s 10-Q, filed May 3, 2023, on SEC EDGAR. View the filing →

Ask your AI about Opko Health's cumulative gross losses and impairments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opko Health's cumulative gross losses and impairments?
Opko Health (OPK) reported cumulative gross losses and impairments of $38.02M in Q4 2022.
What is the long-term trend for Opko Health's cumulative gross losses and impairments?
Over 2 years (2020 to 2022), Opko Health's cumulative gross losses and impairments has grown at a 0.0% compound annual growth rate (CAGR), from $38.02M to $38.02M.
What does cumulative gross losses and impairments mean?
This metric aggregates all unrealized losses and recognized impairment charges on investment securities that have not yet been realized through a sale. It provides a comprehensive view of the negative valuation adjustments impacting the bank's equity. It is a key indicator of the credit and market risk embedded in the bank's long-term holdings.